Peptidoglycan Recognition Protein I alpha (PGRP-Iα) is a pivotal element of the innate immune system, which serves as the first line of defense against pathogenic challenges in organisms. PGRP-Iα specializes in identifying peptidoglycan, a ubiquitous and essential component of bacterial cell walls. This recognition is crucial for the organism's ability to discern non-self entities, such as bacteria, from self. Upon binding with peptidoglycan, PGRP-Iα can initiate a series of immune responses aimed at managing the presence of the detected bacteria. The protein is encoded by a gene that is responsive to signals indicative of bacterial presence, allowing for its expression to be finely tuned in accordance with the level of bacterial exposure. The upregulation of PGRP-Iα is a sophisticated biological response that enhances the organism's capacity to maintain homeostasis in the face of microbial colonization.
There are numerous chemical compounds that can potentially induce the expression of PGRP-Iα. These activators often resemble molecular patterns associated with pathogens and are therefore recognized by the immune system as signals to bolster defense mechanisms. For instance, compounds such as Lipopolysaccharide (LPS) and Lipoteichoic acid (LTA), which are components of bacterial cell walls, can trigger an increase in the expression of PGRP-Iα. Similarly, synthetic analogs like Polyinosinic-polycytidylic acid (Poly I:C) and CpG oligodeoxynucleotides, which mimic viral and bacterial nucleic acids, respectively, can also stimulate the expression of this protein. Other substances, such as Muramyl dipeptide (MDP) and various immune response modifiers like Imiquimod and Resiquimod, have been observed to elevate PGRP-Iα levels. These substances operate by engaging with immune receptors, thereby signaling the presence of potential pathogens and inducing a state of alert in immune cells. The upsurge in PGRP-Iα expression following exposure to such activators reflects the dynamic nature of the immune system and its ability to adapt to diverse microbial encounters.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS, as a principal component of Gram-negative bacterial outer membranes, can initiate a robust immune response. Upon detection by immune cells, LPS can significantly upregulate PGRP-Iα expression as part of the host's effort to recognize and respond to bacterial invasion. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod, recognized by toll-like receptors on immune cells, can prompt a heightened immune surveillance state. This heightened state is characterized by the upregulation of immune-related proteins, including PGRP-Iα, as a countermeasure against pathogenic organisms. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
As a stimulator of immune cell activity, R-848 can trigger a cascade of immune responses, including the elevation of PGRP-Iα expression. This elevation is a strategic move by the immune system to enhance pathogen recognition capabilities. | ||||||
Lipoteichoic acid | 56411-57-5 | sc-507479 | 5 mg | $248.00 | ||
LTA from Gram-positive bacteria is a potent elicitor of the immune response. The detection of LTA by immune receptors can lead to an increase in PGRP-Iα expression, reinforcing the body's defensive barriers against bacterial incursion. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Mimicking bacterial lipoproteins, Pam3CSK4 can stimulate a specific arm of the immune system, leading to the induction of PGRP-Iα. This induction serves as a strategic upscaling of immune readiness in anticipation of bacterial infection. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod, an analog of immune-stimulating compounds found in bacteria, can cause an increase in the expression of PGRP-Iα. The increase is part of the body's innate immune response, aiming to prepare for microbial attack. | ||||||